VEGFA and rheumatoid arthritis: Leflunomide has been shown to inhibit angiogenesis-related endothelial function, and novel biologics, such as the JAK pathway inhibitors, peficitinib and tofacitinib, have been shown to treat RA by inhibiting VEGF expression and angiogenesis (268–270).